Focus on Pharmaceutical Research
José Luis Valverde, G. N. Fracchia
IOS Press, 1999 - Medical - 99 pages
The European Commission's Fifth Framework Programme for Research and Technological Development (1998-2002) has been recently launched. As often the case with new programmes, the time allows for a careful evaluation of the work concluded in the previous programme. This volume, the first in a series on Pharmaceuticals, policy and law, takes stock of the experience gathered in the field of pharmaceutical research in the BIOMED 2 Programme of the EU Fourth Framework Programme(1994-1998) , and attempts an analysis of the needs, opportunities and perspectives in the field from the various points of view of the academia, pharmaceutical industry, regulatory authorities, consumers and patients, including those suffering from rare diseases. The case for a robust system for pharmacovigilance in modern pharmacotherapy and underpinning research is defended.
What people are saying - Write a review
We haven't found any reviews in the usual places.
activity adverse drug reactions antibodies assessment benefit biological biotechnology Centres for Study clinical trials collaboration combinatorial chemistry Community Conference on Harmonisation consumers cost countries CPMP drug development drug regulatory authorities effects efficacy and safety EMEA ethical Europe European Agency European Commission European Union Evaluation of Medicinal experts G.N. Fracchia global guidelines harmonization health care system hippocampal Idänpään-Heikkilä innovation International Conference International Pharmacopoeia investment involved IOS Press issues long-term potentiation major manufacturers manuscript Marketing Authorisation Application medicinal chemistry memory models molecular molecules monoclonal antibodies neuronal orphan drugs orphan medicinal products parallel trade participation Party patients pharmaceutical companies pharmaceutical industry Pharmaceutical Law pharmaceutical research Pharmaceuticals Policy Pharmacoepidemiology pharmacovigilance phocomelia presynaptic procedure Queen's University rare diseases requirements research and development risk role safety and efficacy scientific advice scientific committees specific Spontaneous reporting strategy Study of Pharmaceutical synaptic thalidomide therapy treatment vaccines